Sugi Predict

Sugi Predict / Targets / CNOT7

CNOT7

CCR4-NOT transcription complex subunit 7 · Q9UIV1 · CNOT7 on Sugi Atlas →

2,185 patent compounds predicted against CNOT7, 1,127 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7974620 SCHEMBL7974620 0.58 13/20
SCHEMBL7974538 SCHEMBL7974538 0.57 13/20
SCHEMBL7984710 SCHEMBL7984710 0.55 13/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL7984353) 0.54 13/20
SCHEMBL7985291 SCHEMBL7985291 0.54 13/20
SCHEMBL7985085 SCHEMBL7985085 0.56 12/20
SCHEMBL8352786 SCHEMBL8352786 0.55 12/20
SCHEMBL7988946 SCHEMBL7988946 0.56 11/20
SCHEMBL1947257 SCHEMBL1947257 0.66 10/20
SCHEMBL7974257 SCHEMBL7974257 0.58 10/20
SCHEMBL7991681 SCHEMBL7991681 0.54 10/20
SCHEMBL7984409 SCHEMBL7984409 0.53 10/20
SCHEMBL4534193 SCHEMBL4534193 0.50 10/20
SCHEMBL2956851 SCHEMBL2956851 0.44 10/20
SCHEMBL3843737 SCHEMBL3843737 0.43 10/20
SCHEMBL4532803 SCHEMBL4532803 0.43 10/20
SCHEMBL7987237 SCHEMBL7987237 0.57 9/20
SCHEMBL7973875 SCHEMBL7973875 0.53 9/20
SCHEMBL7974278 SCHEMBL7974278 0.53 9/20
SCHEMBL5771106 SCHEMBL5771106 0.52 9/20

Clinical trials — most relevant to CNOT7 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
Impact of tdrd9 Gene Mutations in the Therapeutic Response to L-carnitine in Oligoasthenozoospermic Men PHASE3ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma PHASE1COMPLETED
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia PHASE1COMPLETED
Implication of CCR4-NOT Complex Subunit 7 Expression in Natural Killer Cell Resistance in Metastatic Breast Cancer nanCOMPLETED
Genetic Studies Spermatogenic Failure nanCOMPLETED
Result Of Karyotyping in Pediatric Patients With Congenital Anomalies and Developmental Delay nanNOT_YET_RECRUITING
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients nanUNKNOWN
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis. nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Chordoma Family Study nanCOMPLETED
The Value of circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
The Genetics of Chiari Type I Malformation nanCOMPLETED
Role of the Nuclear Pore Component RANBP2 in Inflammatory Responses to Viral Infections nanCOMPLETED
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma nanUNKNOWN
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve nanUNKNOWN
Whole Exome Sequencing in Prenatal Diagnosis of Agenesis of the Corpus Callosum nanCOMPLETED
Phenotypic and Genotypic Studies in Congenital and Early Onset Ataxias nanCOMPLETED
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic nanCOMPLETED
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System nanUNKNOWN
Cause of Familial Testicular Cancer nanCOMPLETED
Epidemiological and Genetic Studies of Body Mass Index nanCOMPLETED
CP-EDIT: Cerebral Palsy - Early Diagnosis and Intervention Trial nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a CNOT7 binder may also engage these)

ProteinNameSimilarity
Q5ZJV9 — 1.000 Q5ZJV9 →
Q60809 — 1.000 Q60809 →
Q3ZC01 — 1.000 Q3ZC01 →
Q08BM8 — 1.000 Q08BM8 →
A4II96 — 1.000 A4II96 →
Q3KQ85 — 1.000 Q3KQ85 →
Q9D8X5 — 1.000 Q9D8X5 →
Q9UFF9 — 0.999 Q9UFF9 →
Q9S9P2 — 0.985 Q9S9P2 →
Q9SAI2 — 0.985 Q9SAI2 →
Q9SKZ2 — 0.983 Q9SKZ2 →
Q9LEU4 — 0.982 Q9LEU4 →
Q17345 — 0.966 Q17345 →
O74856 — 0.966 O74856 →
Q9ZVE0 — 0.958 Q9ZVE0 →
Q0WUI9 — 0.957 Q0WUI9 →
Q9LXM2 — 0.956 Q9LXM2 →
O23617 — 0.956 O23617 →
O80738 — 0.954 O80738 →
Q90ZA1 — 0.954 Q90ZA1 →
Q556Y2 — 0.954 Q556Y2 →
Q9LMI0 — 0.954 Q9LMI0 →
Q6NUA1 — 0.952 Q6NUA1 →
PRMT5 Protein arginine N-methyltransferase 5 0.952 landscape →
Q8CIG8 — 0.952 Q8CIG8 →
O81209 — 0.951 O81209 →
Q9ZV48 — 0.951 Q9ZV48 →
Q6PH52 — 0.950 Q6PH52 →
A9RBS1 — 0.950 A9RBS1 →
O80765 — 0.950 O80765 →